KCT0004610已完成未知
A randomized, outcome assessor-blinded, placebo-controlled, single center pilot clinical trial to evaluate the safety and different efficacy of different wavelength of invasive laser medical device combined with electrical stimulator(Ellise) on chronic non speicific low back pain
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- WONTECH
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 70(Year)(—)
- 性别
- All
入选标准
- •Participants meeting all of the following criteria will be included in this trial:1) male or female aged 19 to 70 years; 2) experiencing CLBP lasting for at least the previous three months; 3) Scoring = 40 points on a 100-mm VAS for pain at the time of screening; 4) Korean language fluency that is adequate for reliable completion of all study assessments; and 5) voluntary provision of informed consent.
排除标准
- •The exclusion criteria are as follows: 1) Radicular pain or progressive neurological deficit; 2) diagnosis of serious spinal pathology(e.g., cancer, recent vertebral fracture, spinal infection, and inflammatory spondylitis); 3) presence of serious chronic disease (e.g., cancer, severe cardiovascular, cerebrovascular, liver, kidney disease, or diabetic neuropathy); 4) history of treatment for alcohol/drug dependency or mental diseases(e.g., schizophrenia, demetia, or epilepsy) in the six months preceding enrollment; 5) LBP is not caused by spinal or soft tissue diseases(e.g., trauma, ankylosing spondylitis, fibromyalgia, rheumatoid arthritis, or gout); 6) presence of contradictions for LA or EA, such as blood clotting abnormalities(e.g., hemophilia), severe skin disease in the lumbar region, presence of metalic device in the lumbar spine, or attaching of electronic medical device(e.g.,pacemaker); 7) Previous lumbar spinal surgery within a year or scheduled procedures during the study; 8) pregnancy or planning to become pregnant; and 9) concurrent participation in other clinical trials.
研究者
相似试验
进行中(未招募)
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中(未招募)
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中(未招募)
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中(未招募)
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中(未招募)
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200
